Payment overview · 2025
General Payments
$350.73
16 reported records · 7 companies
Healthcare provider profile · identity verified
Kimberly Chan, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1295166692
Verified facts
What the public records show
CMS Open Payments records show Kimberly Chan, M.D received $350.73 in general payments during 2025 across 16 reported records.
Lilly USA, LLC accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.67 | 28.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.66 | 27.6% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.27 | 13.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.47 | 13.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.67 | 6.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.25 | 5.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.74 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $350.73 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $146.94 | 6 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $45.47 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.16 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.47 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 139 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 303 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 15 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
153 | 93 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
303 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
303 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1069 | 256 |
| Amlodipine Besylate | Amlodipine Besylate | 775 | 217 |
| Losartan Potassium | Losartan Potassium | 563 | 140 |
| Metformin Hcl | Metformin Hcl | 397 | 88 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 383 | 95 |
| Azelastine Hcl | Azelastine Hcl | 306 | 105 |
| Jardiance | Empagliflozin | 303 | 54 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 292 | 167 |
| Cephalexin | Cephalexin | 280 | 182 |
| Lidocaine | Lidocaine | 271 | 64 |
| Icosapent Ethyl | Icosapent Ethyl | 264 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 69 |
| Vascepa | Icosapent Ethyl | 262 | 48 |
| Gabapentin | Gabapentin | 242 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 237 | 60 |
| Montelukast Sodium | Montelukast Sodium | 233 | 89 |
| Famotidine | Famotidine | 232 | 97 |
| Alendronate Sodium | Alendronate Sodium | 212 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 46 |
| Meloxicam | Meloxicam | 154 | 70 |
| Prolia | Denosumab | 153 | 93 |
| Farxiga | Dapagliflozin Propanediol | 139 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 57 |
| Glimepiride | Glimepiride | 132 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 131 | 33 |
| Januvia | Sitagliptin Phosphate | 128 | 24 |
| Tradjenta | Linagliptin | 122 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 26 |
| Mupirocin | Mupirocin | 120 | 82 |
| Allopurinol | Allopurinol | 119 | 34 |
| Simvastatin | Simvastatin | 117 | 26 |
| Finasteride | Finasteride | 105 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 17 |
| Omeprazole | Omeprazole | 91 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 85 | 25 |
| Amoxicillin | Amoxicillin | 84 | 60 |
| Lovastatin | Lovastatin | 82 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 15 |
| Atenolol | Atenolol | 79 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 44 |
| Metformin Hcl Er | Metformin Hcl | 71 | 18 |
| Azithromycin | Azithromycin | 64 | 50 |
| Glipizide | Glipizide | 64 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 29 |
| Hydrocortisone | Hydrocortisone | 62 | 29 |
| Loperamide | Loperamide Hcl | 62 | 53 |
| Carvedilol | Carvedilol | 60 | 18 |
| Donepezil Hcl | Donepezil Hcl | 59 | 15 |
| Trazodone Hcl | Trazodone Hcl | 56 | 26 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 54 | 14 |
| Furosemide | Furosemide | 54 | 24 |
| Telmisartan | Telmisartan | 54 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 52 | 32 |
| Dapagliflozin | Dapagliflozin Propanediol | 52 | 15 |
| Lisinopril | Lisinopril | 52 | 16 |
| Clonidine Hcl | Clonidine Hcl | 50 | 20 |
| Meclizine Hcl | Meclizine Hcl | 48 | 39 |
| Ezetimibe | Ezetimibe | 44 | 11 |
| Naproxen | Naproxen | 44 | 18 |
| Cyclosporine | Cyclosporine | 43 | 13 |
| Restasis | Cyclosporine | 43 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Lansoprazole | Lansoprazole | 42 | 12 |
| Fluocinonide | Fluocinonide | 41 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 35 | 15 |
| Creon | Lipase/Protease/Amylase | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 33 | 23 |
| Ibuprofen | Ibuprofen | 32 | 15 |
| Temazepam | Temazepam | 32 | suppressed |
| Acarbose | Acarbose | 31 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 30 | suppressed |
| Prednisone | Prednisone | 30 | 25 |
| Procto-Med Hc | Hydrocortisone | 30 | 14 |
| Ztlido | Lidocaine | 30 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 28 | 22 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 27 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 26 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Febuxostat | Febuxostat | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Diovan | Valsartan | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | 13 |
| Jentadueto | Linagliptin/Metformin Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 21 | suppressed |
| Lipitor | Atorvastatin Calcium | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Travoprost | Travoprost | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Benicar | Olmesartan Medoxomil | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Ativan | Lorazepam | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $350.73 · 16 records | Lilly USA, LLC | AIRSUPRA, BREZTRI, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, JARDIANCE, PAXLOVID | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error